The results revealed that the false positivity rates of MDM2 IHC for fibroinflammatory diseases (sclerosing mesenteritis and retroperitoneal fibrosis) were 21% (3/14) and 10% (1/10), respectively. This evidence concerns the gene MDM2 and IgG4-related retroperitoneal fibrosis.